1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor
Angela Stefanachi(University of Bari Aldo Moro), Marı́a Isabel Cadavid(Universidade de Santiago de Compostela), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Nuría B. Centeno(Universidade de Santiago de Compostela), Ferrán Sanz(Universitat Pompeu Fabra), José Brea(Universidade de Santiago de Compostela), Marı́a Isabel Loza(Universidade de Santiago de Compostela), Rosa M. Nieto(Universidade da Coruña), Cristina Esteve(Universidade de Santiago de Compostela), Enrique Raviña(Universidade de Santiago de Compostela)
Cited by 26
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
Open Source Drug Discovery with the Malaria Box Compound Collection for Neglected Diseases and Beyond
|PLoS Pathogens|2016|451
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334